Compare Sana Biotechnology Inc (SANA) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Xcel Energy Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Xcel Energy Inc trades at $78.62 (market cap $49.11B). The key difference: Xcel Energy Inc is far larger — about 56.2× Sana Biotechnology Inc's market cap, and Xcel Energy Inc pays a 3.01% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | XEL | |
|---|---|---|
Market Cap | $873.84M | $49.11B |
Sector | Health | Utilities |
52-Week High | $5.92 | $83.91 |
52-Week Low | $2.68 | $71.14 |
Enterprise Value | $848.03M | $86.55B |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
XEL trades at $78.72, down 0.06% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $14.67B in 2025, with a net income margin of 14.14%. Analyst consensus is bullish with a $94.50 price target, and the company maintains a steady dividend, with a recent payout declared for July 2026.
The outlook for XEL is supported by strong analyst buy ratings and a significant capital expenditure plan targeting growth, but risks include regulatory pushback and high debt levels. The stock's current valuation near historical highs requires monitoring of earnings delivery against expectations, particularly the upcoming Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
